Brexit: MHRA updates Guidance
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
On 02 September, the UK Medicine and Healthcare Agency MHRA has published a Guidance called "Importing Medicines on an approved country for import list from 1 January 2021". This Guideline has now been revised providing more information on sourcing medicine from Northern Ireland to Great Britain.
This goes along with an update of other documents issued by MHRA. Although they are designed for UK companies, it will also have an impact on all companies currently supplying medicines into UK from EU 27 Member States, plus a handful of other countries classified as 'approved countries':
- Importing CT Material into UK
- Sourcing of medicines for UK and Northern Ireland
- Acting as RP for products imported into UK from Approved Countries
Even more details about the Northern Ireland situation are summarised in a Guidance called "Supplying medicines to Northern Ireland from 1 January 2021".
Further advice on independent batch release in the UK for biologicals is given in a "Guidance for manufacturers of biological medicines - independent batch release in the United Kingdom from 1 January 2021", focusing on the certification of batches of immunological medicinal products or medicinal products derived from human blood or plasma products (including plasma pools).
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?